First-to-market launch of Bosutinib tablets, 400 mg (a generic equivalent of Bosulif®)

With the first-to-market launch of Bosutinib tablets, 400 mg (a generic equivalent of Bosulif®) in the United States, in collaboration with MSN Laboratories Pvt. Ltd., we are strengthening our oncology portfolio while improving patient access to affordable, high-quality medicines.